Volume | 3,222,314 |
|
|||||
News | - | ||||||
Day High | 6.43 | Low High |
|||||
Day Low | 6.125 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
BioCryst Pharmaceuticals Inc | BCRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
6.23 | 6.125 | 6.43 | 6.31 | 6.44 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
21,019 | 3,222,314 | US$ 6.30 | US$ 20,305,066 | - | 4.03 - 8.96 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:26:34 | formt | 100 | US$ 6.26 | USD |
BioCryst Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.3B | 206.15M | - | 331.41M | -226.54M | -1.10 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioCryst Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCRX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.63 | 6.985 | 6.125 | 6.63 | 3,356,590 | -0.37 | -5.58% |
1 Month | 5.38 | 6.985 | 5.23 | 6.30 | 3,911,970 | 0.88 | 16.36% |
3 Months | 4.87 | 6.985 | 4.03 | 5.34 | 3,712,100 | 1.39 | 28.54% |
6 Months | 5.54 | 7.75 | 4.03 | 5.65 | 3,706,858 | 0.72 | 13.00% |
1 Year | 8.53 | 8.96 | 4.03 | 6.06 | 3,297,028 | -2.27 | -26.61% |
3 Years | 16.37 | 19.99 | 4.03 | 10.38 | 3,237,750 | -10.11 | -61.76% |
5 Years | 3.35 | 19.99 | 1.38 | 7.90 | 4,087,173 | 2.91 | 86.87% |
BioCryst Pharmaceuticals Description
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |